Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-Keratinized Squamous Cell Carcinoma of Nasopharynx.

Next Previous
Trial Profile

Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-Keratinized Squamous Cell Carcinoma of Nasopharynx.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Acronyms Tax-Nazo
  • Sponsors Sanofi

Most Recent Events

  • 22 May 2009 Primary endpoint changed from disease free survival to complete clinical response rate as reported by ClinicalTrials.gov.
  • 09 Nov 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top